BOSTON, March 27, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that results from its completed Phase 2 clinical trial of lead product candidate A4250 in children with Alagille syndrome and biliary atresia have been selected for presentation at the European Association for the Study of the Liver (EASL) The International Liver Congress (ILC) 2019, being held April 10-14, 2019, at the Reed Messe Wien Exhibition & Congress Center in Vienna, Austria.
The Phase 2 trial evaluated A4250 in children with cholestatic liver diseases including Alagille syndrome and biliary atresia. Trial results for patients with Alagille syndrome have been selected for an oral presentation on Saturday, April 13, and results for patients with biliary atresia will be presented during a poster session on Friday, April 12.
Details of the presentations are as follows:
Title: Effects of the ileal bile acid transport inhibitor A4250 on serum bile acids, pruritus and sleep in patients with Alagille syndrome: Phase 2 study results
Presentation Number: PS-194
Session: Parallel session: Clinical developments in rare liver disease
Date / Time: Saturday, April 13, 8:30 a.m. CEST
Presenter: Dr. Ulrich Baumann, Professor of Pediatric Gastroenterology and Hepatology, Hannover Medical School; Hannover, Germany
Title: Effects of the ileal bile acid transport inhibitor A4250 on pruritus and serum bile acids in
patients with biliary atresia: Phase 2 study results
Presentation Number: FRI-060
Session: Poster: Autoimmune and chronic cholestatic liver disease: Clinical aspects
Date / Time: Friday, April 12, 9 a.m. - 5 p.m. CEST
Presenter: Dr. Ekkehard Sturm, Head of Pediatric Gastroenterology-Hepatology, Liver and Intestinal Transplantation, Children's Hospital, University of Tuebingen; Tuebingen, Germany
Also at EASL, the following presentation by Daan van Wessel, University Medical Center Groningen, Netherlands, on April 13 at 8:45 a.m. CEST is relevant to the development of A4250: “Predicting long-term outcome after surgical biliary diversion in BSEP-deficiency patients: Results from the NAPPED consortium” (presentation number PS-195). Notably, the NAPPED consortium data demonstrate the impact of surgical biliary diversion on serum bile acids in bile salt export pump (BSEP)-deficient patients with mild or moderate PFIC type 2. NAPPED is supported by an unrestricted grant from Albireo.
The International Liver Congress is the annual EASL meeting, which brings together more than 10,000 scientific and medical experts from around the world to learn about the latest in liver research. For more information about the conference, visit https://ilc-congress.eu/.
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, A4250, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo’s clinical pipeline also includes two Phase 2 product candidates. Albireo’s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Investor Contact: Hans Vitzthum, LifeSci Advisors, LLC, 212-915-2568
Media Contact: Heather Anderson, 6 Degrees, 980-938-0260, firstname.lastname@example.org
Source: Albireo Pharma, Inc.
Source: Albireo Pharma, Inc.